Madhusudhan Gutta, Chandrababu
Abstract
During the process development of aripiprazole (1) in our lab, one unknown impuritywas detected inHPLCanalysis at levels ranging from0.05 to 2.0%. The unknown impurities have not been reported previously in the preparation of aripiprazole as a bulk drug synthesis. This impuritywas isolated, synthesized and characterized as 7-(4(4-(2,3-dichlorophenyl) piper azin-1-yl)butoxy)quinolin-2(1H)-one, by 1H NMR, IR and mass spectral data.